CN1133431C - 用罗西格列酮和胰岛素治疗糖尿病 - Google Patents

用罗西格列酮和胰岛素治疗糖尿病 Download PDF

Info

Publication number
CN1133431C
CN1133431C CNB988062232A CN98806223A CN1133431C CN 1133431 C CN1133431 C CN 1133431C CN B988062232 A CNB988062232 A CN B988062232A CN 98806223 A CN98806223 A CN 98806223A CN 1133431 C CN1133431 C CN 1133431C
Authority
CN
China
Prior art keywords
chemical compound
pharmaceutically acceptable
insulin
diabetes
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988062232A
Other languages
English (en)
Chinese (zh)
Other versions
CN1260715A (zh
Inventor
��S��A��ʷ����˹
S·A·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1260715A publication Critical patent/CN1260715A/zh
Application granted granted Critical
Publication of CN1133431C publication Critical patent/CN1133431C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988062232A 1997-06-18 1998-06-15 用罗西格列酮和胰岛素治疗糖尿病 Expired - Fee Related CN1133431C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9712866.4 1997-06-18
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (2)

Publication Number Publication Date
CN1260715A CN1260715A (zh) 2000-07-19
CN1133431C true CN1133431C (zh) 2004-01-07

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988062232A Expired - Fee Related CN1133431C (zh) 1997-06-18 1998-06-15 用罗西格列酮和胰岛素治疗糖尿病

Country Status (30)

Country Link
EP (1) EP0999837A1 (id)
JP (1) JP2002504138A (id)
KR (1) KR20010013843A (id)
CN (1) CN1133431C (id)
AP (1) AP1287A (id)
AR (2) AR012997A1 (id)
AU (1) AU8216398A (id)
BG (1) BG104059A (id)
BR (1) BR9810444A (id)
CA (1) CA2294141A1 (id)
CO (1) CO4940454A1 (id)
DZ (1) DZ2521A1 (id)
EA (1) EA004800B1 (id)
GB (1) GB9712866D0 (id)
HU (1) HUP0003260A3 (id)
ID (1) ID23951A (id)
IL (1) IL133143A0 (id)
IN (1) IN189723B (id)
MA (1) MA26511A1 (id)
NO (1) NO996265L (id)
OA (1) OA11517A (id)
PE (1) PE104499A1 (id)
PL (1) PL343123A1 (id)
SK (1) SK179399A3 (id)
TR (1) TR199903095T2 (id)
TW (1) TW587937B (id)
UA (1) UA70299C2 (id)
UY (1) UY25050A1 (id)
WO (1) WO1998057636A1 (id)
ZA (1) ZA985237B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (es) 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Also Published As

Publication number Publication date
TW587937B (en) 2004-05-21
CO4940454A1 (es) 2000-07-24
PL343123A1 (en) 2001-07-30
CN1260715A (zh) 2000-07-19
AU8216398A (en) 1999-01-04
SK179399A3 (en) 2000-11-07
EA004800B1 (ru) 2004-08-26
BR9810444A (pt) 2000-09-05
CA2294141A1 (en) 1998-12-23
KR20010013843A (ko) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
NO996265D0 (no) 1999-12-17
ID23951A (id) 2000-06-08
NO996265L (no) 1999-12-17
UY25050A1 (es) 2000-09-29
BG104059A (en) 2000-10-31
WO1998057636A1 (en) 1998-12-23
IN189723B (id) 2003-04-19
OA11517A (en) 2004-02-04
HUP0003260A3 (en) 2001-12-28
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
HUP0003260A2 (hu) 2001-05-28
ZA985237B (en) 2000-02-17
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
GB9712866D0 (en) 1997-08-20
DZ2521A1 (fr) 2003-02-08
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
IL133143A0 (en) 2001-03-19
UA70299C2 (en) 2004-10-15
TR199903095T2 (xx) 2000-08-21
EA200000042A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
CN1230171C (zh) 用噻唑烷二酮和二甲双胍治疗糖尿病
CN1133431C (zh) 用罗西格列酮和胰岛素治疗糖尿病
CN1443068A (zh) 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物
JP2005213273A (ja) チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
CN1112926C (zh) 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
CN1263467A (zh) 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
CN1168451C (zh) 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
CN1274282A (zh) 用噻唑烷二酮和α－葡糖苷酶抑制剂治疗糖尿病
CN101757627A (zh) 用于治疗糖尿病的联合用药及药物组合物
CN1332638A (zh) 包含β－激动剂和其它抗糖尿病药物的组合物
CN101040854A (zh) 用噻唑烷二酮和二甲双胍治疗糖尿病
CN1235586C (zh) 改进释放组合物及其用途
CN1281358A (zh) 噻唑烷二酮在高血糖症治疗中的应用
CN1281359A (zh) 应用噻唑烷二酮类药物治疗高血糖症
NZ515554A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee